Eran Pras1, Dana Kristal2, Nadav Shoshany3, Dina Volodarsky4, Inna Vulih4, Gershon Celniker5, Ofer Isakov5, Noam Shomron5, Elon Pras6. 1. The Matlow's Ophthalmo-Genetics Laboratory, Department of Ophthalmology, Assaf-Harofeh Medical Center, Zerifin, Israel Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 2. Department of Ophthalmology, Edith-Wolfson Medical Center, Holon, Israel. 3. The Matlow's Ophthalmo-Genetics Laboratory, Department of Ophthalmology, Assaf-Harofeh Medical Center, Zerifin, Israel. 4. Dyn Labs, Assaf-Harofeh Medical Center, Zerifin, Israel. 5. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel Functional Genomics Laboratory, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 6. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel Danek Gartener Institute of Human Genetics, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel.
Abstract
PURPOSE: To explore the molecular basis of familial, early onset, age-related macular degeneration (AMD) with diverse phenotypes, using whole exome sequencing (WES). METHODS: We performed WES on four patients (two sibs from two families) manifesting early-onset AMD and searched for disease-causing genetic variants in previously identified macular degeneration related genes. Validation studies of the variants included bioinformatics tools, segregation analysis of mutations within the families and mutation screening in an AMD cohort of patients. RESULTS: The index patients were in their 50s when diagnosed and displayed a wide variety of clinical AMD presentations: from limited drusen in the posterior pole to multiple basal-laminar drusen extending peripherally. Severe visual impairment due to extensive geographic atrophy and/or choroidal-neovascularisation was common by the age of 75 years. Approximately, 400 000 genomic variants for each DNA sample were included in the downstream bioinformatics analysis, which ended in the discovery of two novel variants; in one family a single bp deletion was identified in the Hemicentin (HMCN1) gene (c.4162delC), whereas in the other, a missense variant (p.V412M) in the Complement Factor-I (CFI) gene was found. Screening for these variants in a cohort of patients with AMD identified another family with the CFI variant. CONCLUSIONS: This report uses WES to uncover rare genetic variants in AMD. A null-variant in HMCN1 has been identified in one AMD family, and a missense variant in CFI was discovered in two other families. These variants confirm the genetic complexity and significance of rare genetic variants in the pathogenesis of AMD. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
PURPOSE: To explore the molecular basis of familial, early onset, age-related macular degeneration (AMD) with diverse phenotypes, using whole exome sequencing (WES). METHODS: We performed WES on four patients (two sibs from two families) manifesting early-onset AMD and searched for disease-causing genetic variants in previously identified macular degeneration related genes. Validation studies of the variants included bioinformatics tools, segregation analysis of mutations within the families and mutation screening in an AMD cohort of patients. RESULTS: The index patients were in their 50s when diagnosed and displayed a wide variety of clinical AMD presentations: from limited drusen in the posterior pole to multiple basal-laminar drusen extending peripherally. Severe visual impairment due to extensive geographic atrophy and/or choroidal-neovascularisation was common by the age of 75 years. Approximately, 400 000 genomic variants for each DNA sample were included in the downstream bioinformatics analysis, which ended in the discovery of two novel variants; in one family a single bp deletion was identified in the Hemicentin (HMCN1) gene (c.4162delC), whereas in the other, a missense variant (p.V412M) in the Complement Factor-I (CFI) gene was found. Screening for these variants in a cohort of patients with AMD identified another family with the CFI variant. CONCLUSIONS: This report uses WES to uncover rare genetic variants in AMD. A null-variant in HMCN1 has been identified in one AMD family, and a missense variant in CFI was discovered in two other families. These variants confirm the genetic complexity and significance of rare genetic variants in the pathogenesis of AMD. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Amy V Jones; Darin Curtiss; Claire Harris; Tom Southerington; Marco Hautalahti; Pauli Wihuri; Johanna Mäkelä; Roosa E Kallionpää; Enni Makkonen; Theresa Knopp; Arto Mannermaa; Erna Mäkinen; Anne-Mari Moilanen; Tongalp H Tezel; Nadia K Waheed Journal: PLoS One Date: 2022-09-06 Impact factor: 3.752
Authors: Rosa L Schellevis; Elon H C van Dijk; Myrte B Breukink; Jan E E Keunen; Gijs W E Santen; Carel B Hoyng; Eiko K de Jong; Camiel J F Boon; Anneke I den Hollander Journal: Mol Genet Genomic Med Date: 2019-02-06 Impact factor: 2.183
Authors: Rinki Ratnapriya; İlhan E Acar; Maartje J Geerlings; Kari Branham; Alan Kwong; Nicole T M Saksens; Marc Pauper; Jordi Corominas; Madeline Kwicklis; David Zipprer; Margaret R Starostik; Mohammad Othman; Beverly Yashar; Goncalo R Abecasis; Emily Y Chew; Deborah A Ferrington; Carel B Hoyng; Anand Swaroop; Anneke I den Hollander Journal: Hum Mol Genet Date: 2020-07-29 Impact factor: 6.150
Authors: Thomas M Hallam; Kevin J Marchbank; Claire L Harris; Clive Osmond; Victoria G Shuttleworth; Helen Griffiths; Angela J Cree; David Kavanagh; Andrew J Lotery Journal: Invest Ophthalmol Vis Sci Date: 2020-06-03 Impact factor: 4.799
Authors: Sarah de Jong; Elena B Volokhina; Anita de Breuk; Sara C Nilsson; Eiko K de Jong; Nicole C A J van der Kar; Bjorn Bakker; Carel B Hoyng; Lambert P van den Heuvel; Anna M Blom; Anneke I den Hollander Journal: Hum Mol Genet Date: 2020-08-11 Impact factor: 6.150